- Home
- ZENV vs CHRS Comparison
ZENV vs CHRS Comparison
Compare ZENV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- CHRS
- Stock Information
- Founded
- ZENV 2005
- CHRS 2010
- Country
- ZENV Brazil
- CHRS United States
- Employees
- ZENV N/A
- CHRS N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENV Technology
- CHRS Health Care
- Exchange
- ZENV Nasdaq
- CHRS Nasdaq
- Market Cap
- ZENV 79.2M
- CHRS 84.2M
- IPO Year
- ZENV 2021
- CHRS 2014
- Fundamental
- Price
- ZENV $1.46
- CHRS $0.95
- Analyst Decision
- ZENV
- CHRS Buy
- Analyst Count
- ZENV 0
- CHRS 3
- Target Price
- ZENV N/A
- CHRS $4.68
- AVG Volume (30 Days)
- ZENV 78.9K
- CHRS 1.3M
- Earning Date
- ZENV 09-04-2025
- CHRS 08-07-2025
- Dividend Yield
- ZENV N/A
- CHRS N/A
- EPS Growth
- ZENV N/A
- CHRS N/A
- EPS
- ZENV N/A
- CHRS N/A
- Revenue
- ZENV $181,911,572.00
- CHRS $272,251,000.00
- Revenue This Year
- ZENV $8.58
- CHRS N/A
- Revenue Next Year
- ZENV $8.83
- CHRS $99.43
- P/E Ratio
- ZENV N/A
- CHRS N/A
- Revenue Growth
- ZENV 23.99
- CHRS 19.87
- 52 Week Low
- ZENV $1.02
- CHRS $0.66
- 52 Week High
- ZENV $3.03
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- ZENV 46.93
- CHRS 59.04
- Support Level
- ZENV $1.40
- CHRS $0.73
- Resistance Level
- ZENV $1.50
- CHRS $0.82
- Average True Range (ATR)
- ZENV 0.09
- CHRS 0.04
- MACD
- ZENV -0.01
- CHRS 0.02
- Stochastic Oscillator
- ZENV 36.36
- CHRS 88.02
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.